IBRX Stock Jumps on Progress in NK Cell Therapy Production [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. The company completed the NK2022 and NK2023 programs, demonstrating that its process for collecting immune cells from blood and converting them into natural killer (NK) cell therapies can be performed safely, consistently and at scale. ImmunityBio successfully conducted apheresis collections (a procedure that separates and collects specific cells from the blood) in 64 subjects, including healthy donors and cancer patients, with no procedure-related serious adverse events reported. The collected cells were then used to validate the company's manufacturing process for generating M-ceNK cells. Per IBRX, a single apheresis collection can produce up to 5 billion NK cells, enough to generate eight to 10 treatment doses per patient within 12 days. Among the
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) was upgraded by BTIG Research to "strong-buy".MarketBeat
- ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]Yahoo! Finance
- IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website